The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
T-lymphoblastic LeukemiaT-lymphoblastic Lymphoma
Interventions
DRUG

Nelarabine injection

Nelarabine is a prodrug of the nucleotide metabolism inhibitor deoxyguanosine analogue 9-β-arabinoguanine (ARA-G). Nelarabine undergoes catalytic transformation by adenosine deaminase (ADA), resulting in the removal of its methoxy group and conversion into ARA-G, Subsequently, ARA-G undergoes sequential monophosphorylation by deoxyguanosine kinase and deoxycytosine nucleoside kinase, yielding the active compound 5'-Guanosine triphosphate (GTP), ARA-GTP. This active compound accumulates within leukemic blast cells and binds to deoxyribonucleic acid (DNA), effectively inhibiting DNA synthesis and ultimately leading to cell death.

Trial Locations (30)

50004

The second Hospital of Hebei Medical University, Shijiazhuang

54001

Xingtai People's Hospital, Xingtai

100049

Aerospace Medical Center, Beijing

100730

Beijing Tongren Hospital,CMU, Beijing

130000

The First Hospital Of Jilin University, Changchun

150001

Affiliated cancer hospital of harbin medical university, Harbin

150010

Institute of Hematology & Oncology, Harbin First Hospital, Harbin

200040

Huashan Hospital Fudan University, Shanghai

201102

Children's Hospital of Fudan University, Shanghai

210008

Nanjing childrens Hospital, Nanjing

210029

Jiangsu Provincial People's Hospital, Nanjing

230000

Anhui Provincial Hospital, Hefei

264200

Weihai Municipal Hospital, Weihai

300202

Tianjin Cancer Hospital, Tianjin

310000

Children's Hospital of Zhejiang University School of Medicine, Hangzhou

400010

Children's Hospital of Chongqing Medical University, Chongqing

400037

The Second Affiliated Hospital of Army Military Medical University, Chongqing

410007

Hunan Children's Hospital, Changsha

430030

Tongji Medical College of HUST, Wuhan

450018

Henan Children's Hospital, Zhengzhou

510062

Sun Yat-sen University Cancer Prevention Center, Guangzhou

530021

Cancer Hospital Affiliated to Guangxi Medical University, Nanning

First Affiliated Hospital of Guangxi Medical University, Nanning

537000

Yulin Red Cross Hospital, Yulin

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

610072

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital, Chengdu

650000

The First Affiliated Hospital of Kunming Medical University, Kunming

710068

Shanxi Provincial People's Hospital, Xi’an

730000

The first hospital of Lanzhou University, Lanzhou

830000

First Affiliated Hospital of Xinjiang Medical University, Ürümqi

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY